MA52812A - Inhibiteurs de sarm1 - Google Patents
Inhibiteurs de sarm1Info
- Publication number
- MA52812A MA52812A MA052812A MA52812A MA52812A MA 52812 A MA52812 A MA 52812A MA 052812 A MA052812 A MA 052812A MA 52812 A MA52812 A MA 52812A MA 52812 A MA52812 A MA 52812A
- Authority
- MA
- Morocco
- Prior art keywords
- sarm1 inhibitors
- sarm1
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682054P | 2018-06-07 | 2018-06-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52812A true MA52812A (fr) | 2021-04-14 |
Family
ID=68770700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052812A MA52812A (fr) | 2018-06-07 | 2019-06-06 | Inhibiteurs de sarm1 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20210261537A1 (https=) |
| EP (1) | EP3801503A4 (https=) |
| JP (1) | JP7481329B2 (https=) |
| CN (2) | CN120398784A (https=) |
| CA (1) | CA3108669A1 (https=) |
| MA (1) | MA52812A (https=) |
| WO (1) | WO2019236890A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112839647B (zh) | 2018-06-07 | 2025-09-23 | 达萨玛治疗公司 | Sarm1抑制剂 |
| CN112839648B (zh) | 2018-06-07 | 2025-04-04 | 达萨玛治疗公司 | Sarm1抑制剂 |
| WO2020081923A1 (en) * | 2018-10-19 | 2020-04-23 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 in combination with nad+ or a nad+ precursor |
| EP3897670A4 (en) | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
| JP7289375B2 (ja) * | 2019-06-06 | 2023-06-09 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１の阻害剤 |
| US12595252B2 (en) | 2019-06-14 | 2026-04-07 | Disarm Therapeutics, Inc. | Inhibitors of SARM1 |
| CA3150878A1 (en) | 2019-09-12 | 2021-03-18 | Jonathan Bentley | Inhibitors of sarm1 |
| JP7528212B2 (ja) * | 2019-11-26 | 2024-08-05 | ディスアーム セラピューティクス， インコーポレイテッド | 神経保護のための方法および組成物 |
| EP4083037A4 (en) * | 2019-12-26 | 2024-01-24 | Yonsei University, University-Industry Foundation(UIF). | Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or tau protein-associated diseases containing same |
| WO2021142006A1 (en) * | 2020-01-07 | 2021-07-15 | Disarm Therapeutics, Inc. | Inhibitors of sarm1 |
| US12435084B2 (en) | 2020-04-09 | 2025-10-07 | Eli Lilly And Company | Indazole derivatives as inhibitors of SARM1 |
| US12606558B2 (en) | 2020-04-09 | 2026-04-21 | Disarm Therapeutics, Inc. | Condensed pyrazole derivatives as inhibitors of SARM1 |
| US12404265B2 (en) | 2020-08-04 | 2025-09-02 | Nura Bio, Inc. | Substituted pyridine derivatives as SARM1 inhibitors |
| TWI904906B (zh) * | 2020-08-24 | 2025-11-11 | 美商達薩瑪治療公司 | Sarm1之抑制劑 |
| CN116438171A (zh) * | 2020-09-16 | 2023-07-14 | 努拉生物公司 | 作为sarm1抑制剂的取代的吡啶衍生物 |
| CN117797146A (zh) * | 2020-11-12 | 2024-04-02 | 科辉智药生物科技（无锡）有限公司 | Sarm1酶活性抑制剂及其在神经退行性疾病中的应用 |
| JP7746384B2 (ja) * | 2020-12-08 | 2025-09-30 | ディスアーム セラピューティクス， インコーポレイテッド | Ｓａｒｍ１のベンゾピラゾール阻害剤 |
| EP4376840A4 (en) | 2021-07-28 | 2025-05-21 | Nura Bio, Inc. | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS |
| WO2023193809A1 (zh) * | 2022-04-08 | 2023-10-12 | 深圳众格生物科技有限公司 | Sarm1抑制剂化合物、包含其的药物组合物及其制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7109208B2 (en) * | 2001-04-11 | 2006-09-19 | Senju Pharmaceutical Co., Ltd. | Visual function disorder improving agents |
| US6989451B2 (en) * | 2002-06-04 | 2006-01-24 | Valeant Research & Development | Heterocyclic compounds and uses thereof |
| US6727241B2 (en) * | 2002-06-12 | 2004-04-27 | Chemocentryx | Anti-inflammatory compositions and methods of use |
| US20060217390A1 (en) * | 2005-02-24 | 2006-09-28 | Esmir Gunic | Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus |
| WO2006133417A1 (en) * | 2005-06-07 | 2006-12-14 | Valeant Pharmaceuticals International | Phenylamino isothiazole carboxamidines as mek inhibitors |
| TWI433677B (zh) * | 2007-06-04 | 2014-04-11 | Avila Therapeutics Inc | 雜環化合物及其用途 |
| IL251949A0 (en) * | 2017-04-26 | 2017-07-31 | Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct | Small organic molecules for use in the treatment of neuro-inflammatory diseases |
| EP3897670A4 (en) * | 2018-12-19 | 2022-09-07 | Disarm Therapeutics, Inc. | MRSA1 INHIBITORS IN COMBINATION WITH NEUROPROTECTIVE AGENTS |
-
2019
- 2019-06-06 CA CA3108669A patent/CA3108669A1/en active Pending
- 2019-06-06 JP JP2021518047A patent/JP7481329B2/ja active Active
- 2019-06-06 CN CN202510537996.8A patent/CN120398784A/zh active Pending
- 2019-06-06 US US16/972,670 patent/US20210261537A1/en active Pending
- 2019-06-06 MA MA052812A patent/MA52812A/fr unknown
- 2019-06-06 WO PCT/US2019/035846 patent/WO2019236890A1/en not_active Ceased
- 2019-06-06 CN CN201980052440.2A patent/CN112867489A/zh active Pending
- 2019-06-06 EP EP19815890.9A patent/EP3801503A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7481329B2 (ja) | 2024-05-10 |
| WO2019236890A1 (en) | 2019-12-12 |
| CN112867489A (zh) | 2021-05-28 |
| EP3801503A1 (en) | 2021-04-14 |
| JP2021527126A (ja) | 2021-10-11 |
| US20210261537A1 (en) | 2021-08-26 |
| CA3108669A1 (en) | 2019-12-12 |
| CN120398784A (zh) | 2025-08-01 |
| EP3801503A4 (en) | 2021-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| MA54550A (fr) | Inhibiteurs de kif18a | |
| EP4007752C0 (en) | Kif18a inhibitors | |
| EP4007753C0 (en) | Kif18a inhibitors | |
| EP3801503A4 (en) | INHIBITORS OF SARM1 | |
| EP4007756C0 (en) | KIF18A INHIBITORS | |
| IL269196A (en) | Novel inhibitors | |
| EP3843714A4 (en) | CD73 INHIBITORS | |
| EP3833355A4 (en) | PRMT5 INHIBITORS | |
| DK3740479T3 (da) | Dna-pk-hæmmere | |
| EP3788042A4 (en) | BCL-2 INHIBITORS | |
| MA52413A (fr) | Inhibiteurs de cd73 | |
| MA52813A (fr) | Inhibiteurs de sarm1 | |
| EP3541932A4 (en) | INHIBITORS OF CRISPR-CAS9 | |
| EP3793547A4 (en) | MAGL INHIBITORS | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| EP3856176A4 (en) | INHIBITORS OF VAP-1 | |
| EP3787635A4 (en) | CD73 INHIBITORS | |
| EP3817736A4 (en) | PIKFYVE INHIBITORS | |
| MA52809A (fr) | Inhibiteurs de sarm1 | |
| EP3980011A4 (en) | INHIBITORS OF SARM1 | |
| EP3773537A4 (en) | STAT3 INHIBITORS | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| EP3856194A4 (en) | INHIBITORS OF VAP-1 |